Drug Trial Radar · NCT01970098
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Last checked: Nov 19, 2026Latest source record: Dec 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
374
Actual
Start
Oct 9, 2013
Primary completion
Jan 2015
Study completion Jan 2015
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.
Conditions
- Spinocerebellar Degeneration
Interventions
KPS-0373, High doseDrug
28 weeks
KPS-0373, Low doseDrug
28 weeks
PlaceboDrug
28 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- SARA (Scale for the Assessment and Rating of Ataxia)Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.